OmniPathology Receives First international Specimens for OP2 HPV Testing from Delta Labs in Saudi Arabia
OmniPathology is pleased to announce that the first international specimens for its proprietary, patent pending oropharyngealHPV swab testing (OP2 HPV) have begun arriving from Delta Labs in Saudi Arabia.
“We commend the leadership of Delta Labs for their proactive approach in offering screening tests to their patients and for entrusting OmniPathology to deliver this valuable service,” said Dr. Mohammad Kamal, CEO of OmniPathology.
Omni and Delta Labs previously announced an international collaboration to expand access to Omni’s proprietary oropharyngeal HPV swab testing. This collaboration marks OmniPathology’s first international partnership and represents a significant step toward expanding global access to its innovative molecular diagnostic testing.
“OmniPathology was founded with a mission to deliver accurate, cutting-edge pathology and molecular diagnostics that improve patient care,” said Dr. Kamal. “We diagnose cancer, but our greater mission is to prevent it. HPV-related oropharyngeal cancer is one of the fastest-growing cancers in the world, and our groundbreaking HPV PCR test is the first HPV throat swab test intended for identifying patients with persistent HPV infection, which is linked to the development of throat cancer. Partnering with Delta Laboratories allows us to extend this important diagnostic tool internationally, starting with Saudi Arabia, and demonstrates our commitment to global healthcare advancement.”
Dr. Hisham Shams, Chief Clinical Officer of Delta Medical Laboratories, added: “At Delta Labs, we are committed to bringing the most advanced diagnostic technologies to patients in the Kingdom of Saudi Arabia and beyond. This partnership with OmniPathology enables us to offer a unique, proprietary test that is not available anywhere else in the region. We look forward to working closely with Dr. Kamal and his team, as this collaboration marks the beginning of broader international initiatives to improve access to state-of-the-art molecular testing.”
This partnership represents the first phase of a long-term collaboration between OmniPathology and Delta Labs to bring specialized molecular testing services to international markets. Both organizations are exploring future opportunities for expanding their test portfolios and research collaborations to advance precision diagnostics worldwide.
For more information on the international collaboration as well as Omni’s OP2 HPV assay, please visit our website at: https://www.omnipathology.com/
